MaaT Pharma

MaaT Pharma

Recherche en biotechnologie

The leading microbiome company in oncology

À propos

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice. Hervé Affagard, CEO & Co-founder

Secteur
Recherche en biotechnologie
Taille de l’entreprise
51-200 employés
Siège social
Lyon
Type
Société cotée en bourse
Fondée en
2014
Domaines
Microbiome, Microbiota, Microbiology, pharma, GvHD, Leukemia, Dysbiosis, Symbiosis, Biotech, oncology, cancer, gut microbiota, allo-HSCT et Gut microbiome

Lieux

Employés chez MaaT Pharma

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement

MaaT Pharma 7 rounds en tout

Dernier round

Titres après introduction en Bourse

1 088 835,00 $US

Voir plus d’informations sur Crunchbase